Tectonic TherapeuticNASDAQ: TECX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$706.65 M
-1%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector
-1%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 80 min ago
$47.90+$3.01(+6.71%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TECX Latest News

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
globenewswire.com11 November 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF.

Tectonic Therapeutic: Interesting CV Disease Drug Developer
seekingalpha.com20 October 2024 Sentiment: POSITIVE

Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027.

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
globenewswire.com19 September 2024 Sentiment: POSITIVE

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial

TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
investorplace.com24 August 2024 Sentiment: NEGATIVE

Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.

Tectonic Therapeutic to Participate in September Investor Conferences
globenewswire.com20 August 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.

What type of business is Tectonic Therapeutic?

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

What sector is Tectonic Therapeutic in?

Tectonic Therapeutic is in the Healthcare sector

What industry is Tectonic Therapeutic in?

Tectonic Therapeutic is in the Biotechnology industry

What country is Tectonic Therapeutic from?

Tectonic Therapeutic is headquartered in United States

What is Tectonic Therapeutic website?

https://tectonictx.com

Is Tectonic Therapeutic in the S&P 500?

No, Tectonic Therapeutic is not included in the S&P 500 index

Is Tectonic Therapeutic in the NASDAQ 100?

No, Tectonic Therapeutic is not included in the NASDAQ 100 index

Is Tectonic Therapeutic in the Dow Jones?

No, Tectonic Therapeutic is not included in the Dow Jones index

When was Tectonic Therapeutic the previous earnings report?

No data

When does Tectonic Therapeutic earnings report?

The next expected earnings date for Tectonic Therapeutic is 29 November 2024